eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
december 2016 (22)
.
.
upgrade to premium
.
january 2016 (24)
.". plemmons added, "particularly in a time when mental health resources for children appear to be static, and woefully scarce across the u.s".
.